Eledon Pharmaceuticals Stock Today
| ELDN Stock | USD 3.51 0.07 2.03% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
Eledon Pharmaceuticals is selling at 3.51 as of the 22nd of March 2025; that is 2.03 percent increase since the beginning of the trading day. The stock's open price was 3.44. Eledon Pharmaceuticals has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of September 2014 | Category Healthcare | Classification Health Care |
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis , and requiring an organ or cell-based transplant. Eledon Pharmaceuticals, Inc. The company has 59.74 M outstanding shares of which 1.18 M shares are currently shorted by private and institutional investors with about 6.44 trading days to cover. More on Eledon Pharmaceuticals
Moving together with Eledon Stock
Moving against Eledon Stock
Eledon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chief President | Steven Perrin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEledon Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eledon Pharmaceuticals' financial leverage. It provides some insight into what part of Eledon Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eledon Pharmaceuticals (ELDN) is traded on NASDAQ Exchange in USA. It is located in 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 and employs 20 people. Eledon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 212.67 M. Eledon Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 59.74 M outstanding shares of which 1.18 M shares are currently shorted by private and institutional investors with about 6.44 trading days to cover.
Eledon Pharmaceuticals currently holds about 70.46 M in cash with (39.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Eledon Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationEledon Pharmaceuticals holds a total of 59.74 Million outstanding shares. Over half of Eledon Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Eledon Ownership Details
Eledon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Awm Investment Company Inc | 2024-12-31 | 1.1 M | |
| Point72 Asset Management, L.p. | 2024-12-31 | 1.1 M | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 933.5 K | |
| Sanofi | 2024-12-31 | 815 K | |
| Zimmer Partners Lp | 2024-12-31 | 750 K | |
| Geode Capital Management, Llc | 2024-12-31 | 663.1 K | |
| Blackrock Inc | 2024-12-31 | 617.6 K | |
| Boothbay Fund Management, Llc | 2024-12-31 | 341.9 K | |
| Velan Capital Investment Management Lp | 2024-12-31 | 324 K | |
| Bvf Inc | 2024-12-31 | 6.3 M | |
| Ra Capital Management, Llc | 2024-12-31 | 3.6 M |
Eledon Pharmaceuticals Historical Income Statement
Eledon Stock Against Markets
Eledon Pharmaceuticals Corporate Management
| Marina Escudero | VP Operations | Profile | |
| Gregory Flesher | Consultant | Profile | |
| Bryan JD | Corporate Counsel | Profile | |
| John Herberger | Vice Operations | Profile | |
| Paul Little | Chief Officer | Profile | |
| David Hovland | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.